Amphetamine

KemPharm Executives to Participate in Panel Discussions During Upcoming June 2021 Conferences

Retrieved on: 
Thursday, June 3, 2021
Psychoactive drugs, Stimulants, Nootropics, Euphoriants, Methylphenidate, Amphetamine, Serdexmethylphenidate, Attention deficit hyperactivity disorder, Idiopathic hypersomnia, Drug, Benzhydrocodone, Dexmethylphenidate

KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH).

Key Points: 
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, stimulant use disorder (SUD) and CNS rare diseases, including idiopathic hypersomnia (IH).
  • KemPharms lead clinical development candidate for the treatment of SUD, KP879, is based on its prodrug of d-methylphenidate, known as serdexmethylphenidate (SDX).
  • In addition, KemPharm has received FDA approval for AZSTARYSTM, a new once-daily treatment for ADHD in patents age six years and older, and for APADAZ, an immediate-release combination product containing benzhydrocodone, a prodrug of hydrocodone, and acetaminophen.
  • For more information on KemPharm and its pipeline of prodrug product candidates visit www.kempharm.com or connect with us on Twitter , LinkedIn , Facebook and YouTube .

Avadel to Present New Efficacy and Safety Data from Pivotal Phase 3 REST-ON Trial of FT218 at SLEEP 2021

Retrieved on: 
Thursday, June 3, 2021
Branches of biology, Sleep disorders, Sleep, Neuroscience, Psychiatric diagnosis, Amphetamine, Narcolepsy, Sleep medicine, Prescription Drug User Fee Act, American Academy of Sleep Medicine, Idiopathic hypersomnia

This joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society is being held virtually from June 10-13, 2021.

Key Points: 
  • This joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society is being held virtually from June 10-13, 2021.
  • Avadel will present FT218 efficacy and safety data from six abstracts, which have been published in an online supplement in the journal Sleep.
  • Details of the presentations are as follows:
    Title: REST-ON: Efficacy of FT218 for Daytime Sleepiness, Sleep Quality, Hallucinations and Sleep Paralysis in Patients with Narcolepsy
    The oral presentation will also be available as a poster.
  • The NDA for FT218 was accepted by the FDA in February 2021 and assigned a PDUFA target action date of October 15, 2021.

Prescription Medication Usage During Pregnancy Has Unknown Effects on Fetal Development

Retrieved on: 
Tuesday, May 25, 2021
Psychiatric diagnosis, Medicine, Health, Psychiatry, Childhood psychiatric disorders, Learning disabilities, Amphetamine, Attention deficit hyperactivity disorder, Educational psychology, Asthma, Autism, Chronic condition

BOCA RATON, Fla., May 25, 2021 /PRNewswire/ --Medication usage during pregnancy has increased substantially over the last several decades.

Key Points: 
  • BOCA RATON, Fla., May 25, 2021 /PRNewswire/ --Medication usage during pregnancy has increased substantially over the last several decades.
  • Over a similar period of time, numerous chronic childhood illnesses have increased including neurodevelopmental delay, autism, asthma, ADHD and autoimmune illnesses.
  • "I see this extraordinary increase in the usage of medication during pregnancy coupled with increases in childhood illnesses, and I wonder if the two are connected.
  • Instead, what are obtained are animal reproductive toxicity data, which are inadequate, as animal species pharmacological data do not extrapolate well to humans.

Qelbree™ (viloxazine extended-release capsules), a New Non-Controlled Substance, Now Available for the Treatment of ADHD in Pediatric Patients 6-17 Years of Age

Retrieved on: 
Monday, May 24, 2021
Psychoactive drugs, Psychiatry, Attention deficit hyperactivity disorder, Amphetamine, Methylphenidate, Childhood psychiatric disorders, Educational psychology, Pemoline, Caregiver, Stimulant, Suicidal ideation, Attention deficit hyperactivity disorder management

Many of my patients and their caregivers seek non-stimulant options as we work together to develop a treatment regimen.

Key Points: 
  • Many of my patients and their caregivers seek non-stimulant options as we work together to develop a treatment regimen.
  • Supernus has developed a robust patient access program to support those who qualify for treatment.
  • As a non-controlled substance that has a unique profile of proven efficacy, safety, and tolerability, Qelbree provides patients living with ADHD a novel treatment option like no other ADHD medication.
  • Qelbree may increase suicidal thoughts and actions in some children with ADHD, especially within the first few months of treatment or when the dose is changed.

Social & Health Research Center and Quest Diagnostics Team Up to Address Childhood Hunger and Obesity Exacerbated by COVID-19 in Underserved Communities

Retrieved on: 
Monday, May 24, 2021
Articles, Health, Determinants of health, Health care quality, Public health, Amphetamine, Body shape, Obesity, Childhood obesity

Dr. Trevio is the principal investigator of the two largest trials funded by the National Institutes of Health to prevent obesity and diabetes in children.

Key Points: 
  • Dr. Trevio is the principal investigator of the two largest trials funded by the National Institutes of Health to prevent obesity and diabetes in children.
  • "We are eager to help our children develop healthy habits by moving this effort forward with SAHRC and Quest Diagnostics.
  • "We know childhood obesity is dramatically growing in underserved communities and that these resources are needed throughout the United States.
  • Quest for Health Equity is an initiative of Quest Diagnostics and the Quest Diagnostics Foundation ),focused on providing resources, funding, testing services and education to address health disparities in underserved communities across the U.S.
    View original content to download multimedia: http://www.prnewswire.com/news-releases/social--health-research-center-a...

Koios Beverage Corp.: Fit Soda™ to be Carried in Over 100 Southwestern U.S. Locations of a National Convenience Chain with Over 3,800 Stores, Starting in June 2021

Retrieved on: 
Thursday, May 20, 2021
Amphetamine, Nootropic, Stimulant

Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well.

Key Points: 
  • Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well.
  • Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants.
  • Koios products have been shown to enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity.
  • As each individual is different, the benefits, if any, of taking the Company\xe2\x80\x99s products will vary from person to person.

XWPharma Announces Abstract for XW10172 Accepted for Presentation at the Associated Professional Sleep Societies SLEEP 2021 Annual Meeting

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Sleep disorders, Glutamate, Neurochemistry, Psychoactive drugs, General anesthetics, Neurotransmitters, Amphetamine, Narcolepsy, gamma-Hydroxybutyric acid, Excessive daytime sleepiness, AMPA

The drug and formulation are designed to deliver oxybate without the sodium content of other products that is associated with increased cardiovascular health risk and monitoring requirements.

Key Points: 
  • The drug and formulation are designed to deliver oxybate without the sodium content of other products that is associated with increased cardiovascular health risk and monitoring requirements.
  • XWPharma's expertise in drug design is focused on providing potential first- and best-in-class medicines with differentiated features to address the unmet medical needs of patients suffering from debilitating neurological diseases.
  • XW10172 is a clinical-stage conjugate of the GABAB agonist, oxybate, in development as an investigational once-nightly therapy intended to regulate the patient\xe2\x80\x99s sleep cycle in order to alleviate excessive daytime sleepiness and other consequences of sleep dysfunction associated with neurodegenerative diseases, including Parkinson\xe2\x80\x99s disease and narcolepsy.
  • XW10508 is a glutamatergic NMDA antagonist and AMPA activator in development as an oral, once-daily therapy with potential abuse deterrent properties, designed for the treatment of major depressive disorder and chronic pain.\n"

Study reveals potential new way to burn fat faster

Retrieved on: 
Tuesday, May 18, 2021
Obesity, Amphetamine, Bariatrics, Body shape, Nutrition, Medical specialties, Branches of biology, Clinical medicine, Diet-induced obesity model

"But our novel findings indicate that increasing activity along one particular axis of inflammation actually prevents weight gain in mice given obesity-inducing diets.

Key Points: 
  • "But our novel findings indicate that increasing activity along one particular axis of inflammation actually prevents weight gain in mice given obesity-inducing diets.
  • Mice bred to utterly lack these proteins gained weight at a rapid pace.\nThis study was the first to highlight how these proteins drive a multi-faceted mechanism on different types of fat.
  • One mechanism was observed to cause white fat, the tissue which in excess leads to obesity, to break down into its original building blocks.
  • The team found that the BAFF/APRIL activity on white fat seen in mice also occurs in humans.

2021 Worldwide Attention Deficit Hyperactivity Disorder Industry - Understand Targeted Population for Research and Development - ResearchAndMarkets.com

Retrieved on: 
Monday, May 17, 2021
Health, General Health, Psychiatric diagnosis, Psychiatry, Medicine, Articles, Childhood psychiatric disorders, Attention deficit hyperactivity disorder, Amphetamine, Educational psychology, Attention deficit, Disease, Attention deficit hyperactivity disorder controversies, Bipolar disorder

b'The "Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow Analysis - 2021, provides Attention Deficit Hyperactivity Disorder epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow Analysis - 2021, provides Attention Deficit Hyperactivity Disorder epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Attention Deficit Hyperactivity Disorder patients, history of the disease at the population level (Attention Deficit Hyperactivity Disorder prevalence, Attention Deficit Hyperactivity Disorder incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nAttention Deficit Hyperactivity Disorder patient flow: Attention Deficit Hyperactivity Disorder prevalence, diagnosed, and drug-treated patients\nDemographics: Attention Deficit Hyperactivity Disorder patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Attention Deficit Hyperactivity Disorder market sizing, assessing market potential, and developing drug forecast models\nIdentify Attention Deficit Hyperactivity Disorder patients segments through age groups, gender, and disease sub-types\nEvaluate Attention Deficit Hyperactivity Disorder market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005615/en/\n'

2021 Global Obesity Epidemiology and Patient Flow Market Report - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 13, 2021
Fitness & Nutrition, Health, Other Health, Obesity, Bariatrics, Body shape, Amphetamine, Nutrition, Medical specialties, Clinical medicine, Branches of biology, Epidemiology of obesity, Draft:Obesity in South Korea

b'The "Global Obesity Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Obesity epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Obesity Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Obesity epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Obesity patients, history of the disease at the population level (Obesity prevalence, Obesity incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Obesity patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Obesity market sizing, assessing market potential, and developing drug forecast models\nIdentify Obesity patients segments through age groups, gender, and disease sub-types\n'